Does Ciprofloxacin (Cipro) interact with Dalteparin (Fragmin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ciprofloxacin Does Not Interact with Dalteparin (Fragmin)

There is no significant interaction between ciprofloxacin (Cipro) and dalteparin (Fragmin), and these medications can be safely administered together.

Understanding Dalteparin (Fragmin)

  • Dalteparin is a low-molecular-weight heparin (LMWH) used for prevention and treatment of venous thromboembolism 1
  • It has advantages over unfractionated heparin including ease of subcutaneous administration, no need for monitoring, less platelet stimulation, and lower risk of heparin-induced thrombocytopenia 1
  • Dalteparin has been extensively studied in clinical trials for various indications including unstable coronary artery disease, venous thromboembolism prophylaxis, and treatment 1

Ciprofloxacin and Anticoagulant Interactions

  • While ciprofloxacin has documented interactions with warfarin that can lead to increased anticoagulant effects and bleeding risk 2, 3, 4, there are no documented interactions between ciprofloxacin and dalteparin in the medical literature or guidelines 1
  • The mechanism of interaction between ciprofloxacin and warfarin involves alteration of R-warfarin metabolism and reduction of clotting factors II and VII 5, but this mechanism is not relevant to dalteparin, which works through a different anticoagulation pathway 1
  • Studies examining ciprofloxacin's interaction with warfarin show inconsistent results, with some showing significant increases in INR and bleeding risk 2, 3, while others show minimal or no clinically significant interaction 5, 6

Clinical Implications

  • Unlike warfarin, which requires careful monitoring of INR when co-administered with certain antibiotics, dalteparin does not require routine laboratory monitoring when used with ciprofloxacin 1
  • Guidelines discussing dalteparin do not list ciprofloxacin as a medication that interacts with it or increases bleeding risk when co-administered 1
  • When considering medication interactions with anticoagulants, it's important to distinguish between vitamin K antagonists (like warfarin) and LMWHs (like dalteparin), as they have different interaction profiles 1

Important Considerations

  • While there is no specific interaction between ciprofloxacin and dalteparin, patients should still be monitored for signs of bleeding, as both medications independently can increase bleeding risk 1
  • If a patient develops unusual bleeding while taking both medications, medical attention should be sought, although this would not be due to a direct interaction between the drugs 7
  • For patients undergoing surgical procedures while on dalteparin, the European guidelines recommend stopping dalteparin more than 12 hours before operation, regardless of concomitant ciprofloxacin use 1

Conclusion

  • Ciprofloxacin and dalteparin (Fragmin) can be safely co-administered without dose adjustments or special monitoring 1
  • This differs from ciprofloxacin's interaction with warfarin, which can require closer monitoring and potential dose adjustments 2, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ciprofloxacin-warfarin coagulopathy: a case series.

American journal of hematology, 2000

Research

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996

Guideline

Management of Hematuria in Patients on Anticoagulation Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.